書籍詳細

第1章 疫学

P.9 掲載の参考文献

• 1) 全国子宮体癌調査成績, 第1報, 第2報:日産婦子宮癌登録委員会, 1980, 1981.

• 2) 野田起一郎, 柳川 洋, 栗原操寿ほか:子宮体がん患者対照研究. 癌の臨床 29:1733, 1983.

• 3) 滝 一郎, 飯島 宏, 田中祥照:実験的にみた子宮癌発生. 現代産科婦人科大系8D-子宮癌総論, 子宮体癌-,pp 49-95, 中山書店,東京, 1970.

• 4) Bokhman JV:Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10, 1983,
  pubmed

• 5) 蔵本博行, 上坊敏子, 大河原聡:若年体癌の諸問題. 産と婦 9:1703, 1988.
  Medical*Online

• 6) 山川義寛,:平井康夫, 中山一武ほか:若年性子宮体癌の臨床病理学的検討. 日産婦誌 43:45, 1991.

• 7) 野田起一郎:子宮癌登録委員会報告. 日産婦誌 39:1927, 1987.

• 8) Kempson RL, Pokorny GE:Adenocarcinoma of the endometrium in women aged forty and younger. Cancer 21:650, 1968.
  pubmed

• 9) Silverberg SG:The disease in young women. In Endometrial Carcinoma and its Treatment III(ed by Gray LA, Thomas CC), Springfield, 1977.

• 10) 加藤久盛, 荒木 勤:若年性子宮体癌の問題点. 産婦実際 37:877, 1988.

• 11) Jafari K, Javaheri G. Ruiz G:Endometrial adenocarcinoma and the Stein-Leventhal syndrome. Obstet Gynecol 51:97, 1978.
  pubmed

• 12) Jeffery JD, Taylor R. Robertson DI. et al:Endometrial carcinoma occuring in patients under the age of 45 years. Am J Obstet Gynecol 156:366, 1988.

• 13) 上坊敏子, 大河原聡, 土屋元一ほか:若年子宮体癌の臨床病理学的検討. 日癌治療会誌 24:2362, 1989.

• 14) Dockerty MB, Lovelady SB, Foust GT Jr:Carcinoma of the corpus uteri in young women. Am J Obstet Gynecol 61:966, 1951.
  pubmed

• 15) 増淵一正, 鈴木忠雄, 鈴村博一:子宮癌を含む重複癌について. 癌の臨床 16:982, 1970.

• 16) Lynch HT, Harris RE, Lynch PM, et al:Role of heredity in multiple primary cancer. Cancer 40:1849, 1977.
  pubmed

• 17) 日本病理剖検輯報, 第1輯〜第25輯 (1959〜1984). 日本病理学会編, 杏林書院, 東京.

• 18) 蔵本博行, 上坊敏子, 土屋元一:婦人科領域の重複癌について. 産婦実際 34:1125, 1985.

• 19) Campbell LV Jr, Wathe AL:Multiple primary malignant neoplasms. Arch Surg 99:401, 1969.

• 20) Cook GB:A comparison of single and multiple primary cancers. Cancer 19:959, 1966.

• 21) Bailar JC:The incidence of independent tumors among uterine cancer patients. Cancer 16:842, 1963.
  pubmed

• 22) Buchler DA:Multiple primaries and gynecologic malignancies. Am J Obstet Gynecol 123:376, 1975.
  pubmed

• 23) Malkasian GD, Annegers JF, Fountain KS:Carcinoma of the endometrium; stage I. Am J Obstet Gynecol 136:872, 1980,

• 24) 鈴木光明, 大和田倫孝, 関口 勲ほか:子宮体癌の臨床病理学的検討. 産婦実際 34:655, 1985.

• 25) Moertel CG, Dockerty MB, Baggenstoss AH:Multiple primary malignant neoplasms. Cancer 14:221, 1961.
  pubmed

• 26) MacMahon B, Austin JH:Association of carcinomas of the breast and corpus uteri. Cancer 23:275, 1969.
  pubmed

• 27) 水内英充, 田村 元, 塚原国比古ほか:子宮体癌を含む重複癌について. 産婦実際 33:1241, 1984.

• 28) Horii A, Han HJ, Shimada M, et al:Frequent replication errors at micro-satellite loci in tumors of patients with multiple primary cancers. Cancer Res 54:3373, 1994.

• 29) Lynch HT, Krush AT, Larsen AL, et al:Endometrial carcinoma; multiple primary malignancies, constitutional factors, and heredity. Am J Med Sci 252:381, 1966.
  pubmed

• 30) 牛尾恭輔, 石川 勉, 牟田浩実ほか:遺伝性非ポリポーシス大腸癌 (HNPCC). 日本臨牀 53:2790, 1995.
  Medical*Online

• 31) Papadopoulos N, Nicolaides NC, Wei YF, et al:Mutation of a mutl homolog is associated with hereditary colon cancer. Science 263:1625, 1994,

• 32) Leach FS, Nicolaides NC, Papadopoulos N, et al:Mutations of a muts homolog in hereditary non-polyposis colorectal cancer. Cell 75:1215, 1993.

• 33) Nicolaides NC, Papadopoulos N, Liu B, et al:Mutations of two PMS homologues in hereditary non-polyposis colon cancer. Nature 371:75, 1994.

• 34) Risinger JI, Berchuck A, Kohler MF, et al:Genetic instability of micro-satellites in endometrial carcinoma. Cancer Res 53:5100, 1993.

P.16 掲載の参考文献

• 1) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会編:子宮体癌取扱い規約. 金原出版, 東京, 1987.

• 2) 矢島正純ほか:子宮の前癌病変とその対策. 臨床科学 27:1482-1489, 1991

• 3) Kurman RJ, et al:The endometrium. The pathology of incipient neoplasia, in Henson DE, Albores Scavedra J (eds), pp 256-277, WB Saunders Co, Philadelphia, 1986.

• 4) 並木恒夫:早期体癌, 間質浸潤, 筋層内浸潤, 乳頭状腺癌および境界病変について. 日婦病理 コルポ誌 7:193-197, 1989.

• 5) McBride JM:Pre-menopausal cystic hyperplasia and endometrial carcinoma. J Obstet Gynecol Br Emp 66:288-296, 1959,

• 6) Kurman RJ, et al:The behavior of endometrial hyperplasia. Cancer 56:403-412, 1985
  pubmed

• 7) Wagner D, et al:Deoxyrlbonuclec acid content of presumed precursors of endometrial carcinoma. Cancer 20:2067-2077, 1967.
  pubmed

• 8) Welch WR, et al:Precancerous lesions of the endometrium Hum Pathol 8:503-512, 1977,
  pubmed

• 9) Gusberg SB, et al:Precursors of coupus cancer. Am J Obstet Gynecol 87:662-678, 1963.

• 10) Wentz WB:Progestin therapy in endometrial hyperplasia. Gynecol Oncol 2:362-367, 1974.
  pubmed

• 11) Chamilian DL, et al:Endometrial hypcrplasia in young woman. Obstet Gynecol 36:659-666, 1970.

• 12) 山辺 徹:子宮体癌に前癌病変はあるか. 臨婦産 45:272-273, 1991.

• 13) Koss LG:Detection of endometrial carcinoma and hyperplasia in a symptomatic woman. Obstet Gynecol 64:1-11, 1984,

• 14) 矢嶋 聰, 佐藤信二:子宮内膜増殖症. Oncol Chemoth 7:353-358, 1991.

• 15) 蔵本博行ほか:子宮体癌に随伴する内膜増殖症-体癌の発生と予後判定の指標としての意義について-. 日婦病理コルポ誌 7:179-184, 1989.

• 16) Feremczu A, et al:The biologic significance of cytologic atypia in progestogen-treated endometnal hyperplasia. Am J Obstet Gynecol 160:126-131, 1989,
  pubmed

• 17) Bokhman JV:Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10-17, 1983.
  pubmed

• 18) 蔵本博行:高齢者の体癌は若年者とどう違うか. 臨婦産 45:264-265, 1991.

• 19) 森脇昭介:子宮内膜増殖症の病理. 病理と臨床7:17-24, 1989.

• 20) 塚崎克己ほか:子宮体癌に進行した内膜増殖症におけるモノクローナル抗体MNS-1が認識する抗原の発現動態の解析. 日産婦誌47:667-674, 1990.

第2章 診断

P.25 掲載の参考文献

• 1) 日産婦学会癌検診問題委員会報告 (委員長, 栗原操寿):子宮体癌検診について.日産婦誌 36:1291, 1984.

• 2) 蔵本博行, 上坊敏子, 下田隆夫:子宮体癌検診の基本的考え方. 癌と化療 12:2251, 1985.
  Medical*Online

• 3) 日本母性保護医協会:子宮体がん検診の手引き. pp 15, 1986.

• 4) 蔵本博行:内膜診断における細胞診と組織診. 臨婦産 46:756, 1992.

• 5) 蔵本博行, 上坊敏子, 森沢孝行:子宮体癌の一次検診. 産婦治療 55:300, 1987.

• 6) 大野英治, 蔵本博行:細胞診による子宮体癌の組織分化度判定. 日臨細胞誌 27:449, 1988.

• 7) 林 玲子:正常ならびに腫瘍性子宮内膜細胞の核計測. 日臨細胞誌 31:457, 1992.

• 8) 蔵本博行:カラーアトラス子宮体癌検診. 医歯薬出版, 東京, 1988.

• 9) 森沢孝行, 蔵本博行, 今井忠明ほか:子宮内膜腺腫性増殖症の細胞診. 日臨細胞誌30:15, 1991.

• 10) 蔵本博行:子宮内膜細胞診. 臨婦産43:369, 1989.

• 11) 厚生省老人保健課・監修:老人保健法による健康診査マニュアル. pp 85, 日本公衆衛生協会, 東京, 1987.

• 12) 昭和56・57年度厚生省がん助成金による「子宮体がんの高危険群に関する研究」 (主任研究者, 野田起一郎). 同研究報告モノグラフ, 1983.

• 13) 蔵本博行, 上坊敏子, 大河原聡ほか:体がん検診-検診対象の拡大が望まれる. 産婦治療 66:174, 1993.

• 14) 蔵本博行:子宮頸癌・体癌の若年化. 臨婦産47:1394, 1993.

P.38 掲載の参考文献

• 1) 子宮体がん検診の手引き. 日本母性保護医協会編, 1986.

• 2) 長谷川壽彦ほか:子宮体癌の術前診断-細胞診-. 産と婦 57:1853-1859, 1990.
  Medical*Online

• 3) 石井保吉ほか:子宮内膜腺癌および関連病変における組織構築の解析 (第一報), 日臨細胞誌 29:487-492, 1990.

• 4) 布引 治ほか:子宮内膜細胞診における新しい標本作成の試み. 日臨細胞誌 31:613-620, 1992.

• 5) 小畑孝四郎ほか:子宮内膜増殖症の細胞像. 日臨細胞誌 30:460-466, 1991.

• 6) 篠原道與:子宮体癌検診の精度管理に関する研究-細胞診と組織診併用の成績から-. 日臨細胞誌 33:489-494, 1994.

• 7) 石井保吉ほか:体内膜細胞診における腺腫性増殖症および高分化型体内膜腺癌の判定基準について. 日臨細胞誌30:651-656, 1991.

• 8) 石井保吉ほか:内膜細胞診における腺腫性増殖症およびGI腺癌の判定基準について. 日臨細胞誌 30:1043-1049, 1991.

• 9) 大野英治ほか:細胞診による子宮体癌の組織分化度判定. 日臨細胞誌 27:449-458, 1988.

• 10) 上坊敏子ほか:子宮体癌の境界病変とその細胞診. 日臨細胞誌 31:11-20, 1992.

• 11) 森一朗:子宮内膜の細胞学的診断に関する研究-とくに組織構築を中心に-. 日臨細胞誌 32:937-947, 1993.

• 12) 岩成 治ほか:子宮内膜細胞診のscoringに関する検討. 日臨細胞誌 29:869-876, 1990.

P.53 掲載の参考文献

• 1) Kurman RJ, Kaminski PF, Norris HJ:The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 49:2547, 1985.

• 2) Ferenczy A, Gelfand M:The biologic significance of cytologic atypia in progestogen-treated endometerial hyperplasia. Am J Obstet Gynecol 160:126, 1989.

• 3) Baak JPA, Wise-Brekelmans ECM, Fleege JC, et al:Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometric features alone. Pathol Res Pract 188:856, 1992,

• 4) 日本産科婦人科学会 日本病理学会 日本医学放射線学会編:子宮体癌取扱規約 改訂第2版, 金原出版, 1996.

• 5) Kurman RJ, Norris HJ:Endometrial hyperpalsia and related cellular changes. In:Pathology of the female genital tract, Kurman RJ, ed, 4th ed, P 411, 1994.

• 6) Kurnlan RJ, Norris HJ:Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well differentiated carcinoma, Cancer 49:2547, 1982.

• 7) Norris HJ, Tavossoli FA, Kurman RJ:Endometrial hyperplasia and carcinoma. Diagnostic considerations. Am J Surg Pathol 7:839, 1983.

• 8) Hendricks on MR, Ross JC, Kempson RL:Toward the development of morphologic criteria for well-differentiated adenocarcinoma of the endometrium. Am J Surg Pathol 7:819, 1983.

• 9) 中島伸夫:異型増殖症と高分化腺癌との鑑別. 取扱規約にそった腫瘍鑑別診断アトラス・子宮体部 (森脇昭介, 杉森 甫編), p 23, 文光堂, 1993.

• 10) Tobon H, Watkins GJ:Secretory adenocarcinoma of thc endometrium. Int J Gynecol Pathol 4:328, 1985,

• 11) Kurman RJ, Scully RE:Clear cell carcinoma of the endometrium:An analysis of 21 cases. Cancer 37:872, 1976.
  pubmed

• 12) Hendrickson MR, Kempson RL:Ciliated carcinoma-avariant of endometrial adenocarcinoma:a report of 10 cases. Int J Gynecol Pathol 2:1, 1983,
  pubmed

• 13) 並木恒夫, 濱中貴久子, 笹野公伸:子宮体部内膜型腺癌と分化度. 取扱規約に沿った腫瘍鑑別診断アトラス・子宮体部 (森脇昭介, 杉森 甫編), p 30, 文光堂, 1993.

• 14) Kurman RJ, Zaino RJ, Norris HJ:Endometrial carcinoma, In; Pathology of the female genital tract, Kurman RJ, ed, 4th ed, p 439, 1994.

• 15) Chen JL, Trost DC, Wilkinson EJ:Endometrial papillary adenocarcinoma:Two clinicopathological types. Int J Gynecol Pathol 4:279, 1985.
  pubmed

• 16) Christopherson WM, Alerhasky RC, Connelly PJ:Carcinoma of the endometrium. II. Papillary adenocarcinoma:A clinical pathological study 46 cases, Am J Clin Pathol 77:534.1982.

• 17) 森脇昭介, 万代光一:子宮体部漿液性腺癌の組織像と悪性度. 取扱規約に沿った腫瘍鑑別診断 アトラス・子宮体部 (森脇昭介, 杉森 甫編), p 42, 文光堂, 1993.

• 18) Snverberg SC, De Giorgi LS:Clear cell carcinoma of the endomctrium. Cancer 31:1127, 1973.

• 19) Christopherson WM, Alberhasky RC, Connelly PJ:Carcinoma of the endometrium. I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 49:1511, 1982.
  pubmed

• 20) van Hoeven KH, Hudock JA, Woodruff JM, et al:Small cell neuroendocrine carcinoma of the endometrium. Int Gynecol Pathol 14:21, 1995.
  pubmed

• 21) Hunsman DG, Clement MD, Gilks CB, et al:Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol 18:364, 1994.

P.71 掲載の参考文献

• 1) 関場 香, 河野一郎:子宮体癌診断におけるヒステロスコピーの有用性について. 産婦人科治療 41:487-491, 1980.

• 2) 園田隆彦:体癌進行期分類の諸問題. 産科と婦人科 49:1132-1140, 1982.
  Medical*Online

• 3) Brueschke EE, Wilbanks GD:Asteerable fibrooptic hysteroscope. Obstet Gynecol 44:273, 1974.

• 4) 林 保良ほか:Flexible hysterofiberscopeの開発および臨床応用. 日産婦誌 39:649, 1987.

• 5) 高橋峰夫:子宮体癌の筋層浸潤並びに頸部浸潤に関する臨床病理学的検討-術前のCT・内視鏡の有用性について-. 慶應医学 66:511-526, 1989.

• 6) 高島英世:カラーアトラス子宮鏡検査-細胞像・組織像との相関. 金原出版, 1997.

• 7) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会編:子宮体癌取扱い規約, 改訂第2版, 金原出版, 1996.

• 8) 杉本 修:体癌/第3章, 診断2ヒステロスコピー. 図説臨床「癌」シリーズNo 12子宮頸癌・体癌, pp 125-130, メディカルビュー社, 1987.

P.87 掲載の参考文献

• 1) 井筒 睦, 小林成司:Dynamic CTとCT angiography. 画像診断セミナー2, 平松京一編, 造影手技のポイント, pp 149-155, 秀潤社, 1993.

• 2) Katayama H, Yamaguchi K, Kozuka T, et al:Adverse Reactions to Ionic and Non-lonic Contrast Media. Radiology 175:621-628, 1990.

• 3) 鈴木正彦, 高橋康, 小島良博:体癌の筋層浸潤度のCT診断. 産と婦 52:642-646, 1985.

• 4) Farrer-Brown G, Beilby JOW, Tarbit MH:The blood supply of the uterus 1. Arterial vasculature. J Obstet Gynecol Br Comm 77:673-681, 1970.

• 5) Farrer-Brown G, Beilby JOW, Tarbit MH:The blood supply of the uterus 2. Venouspattern. J Obstet Gynecol Br Comm 77:682-689, 1970.

• 6) 富樫かおり:骨盤内膜症. 婦人科疾患のMRI診断, pp 169-187, 医学書院, 1990.

• 7) Higuchi N, Oshio K, Imai Y, et al:Clinical applications of multi-shot RARE in abdominal MR imaging. SMRI Abstract pp 150-151, 1991.

• 8) 井筒 睦:子宮内膜癌の Dynamic MRI. 日磁医誌 13:11-22, 1993.

• 9) Lee JKT, Gersell DJ, Balfe DM, et al:The uterus. In vitro MR-anatomic correlation of normal and abnormal specimens. Radiology 157:175-179, 1985.

• 10) Worthington JL, Balfe DM, Lee JKT, et al:Uterine neoplasmas; MR imaging. Radiology 159:725-730, 1986.

• 11) McCarthy S, Scott G, Majumdar S, et al:MR study of water content and relaxation properties, Radiology 171:241-243, 1989.
  pubmed

• 12) Hricak H, Alpers C, Crooks LE, et al:Magnetic resonance imaging of the female pelvis. Initial experience. AJR 141:1119-1128, 1983.
  pubmed

• 13) Demas BE, Hricak H, Jaffe RB:Uterine MR imaging. Effects of hormonal stimulation. Radiology 160:119-123, 1986.

• 14) McCarthy S, Tauber C RT, Gore J:Female pelvic anatomy; MR assessment of variations during the mens trual cycle and with use of oral contraceptives. Radiology 160:119-123, 1986.

• 15) Hricak H Hamm B, Semelka RC, et al:Carcinoma of the uterus. Use of gadopentetate dimeglumine in MR imaging. Radiology 171:95-106, 1991.

• 16) 松本富美子, 馬淵順久, 吉岡寛康:子宮体癌における造影MRIの有用性の検討. 日本医放会誌 51:33-43, 1991.

• 17) Hricak H, Stern JL, Fisher MR, et al:Endometrial carcinoma staging by MR imaging. Radiology 162:297-305, 1987.
  pubmed

• 18) 伊東克能, 藤田信行, 小川 肇ほか:MRIの子宮内膜癌筋層浸潤診断における有用性について. 日磁医誌 11:129-133, 1991.

P.94 掲載の参考文献

• 1) Sekiba K, Yuhara A, Akamatsu N, et al:Radial scan ultrasonography for estimating the extent of cervical carcinoma. Ultrasound and Cancer(Levi S ed), pp 137, Excepta Medica, Amsterdam, Oxford, Princeton, 1982,

• 2) Fleisher AC, Dudly BS, Entmann SS, et al:Myometrial invasion by Endometrial Carcinoma; Sonographic Assessment, Radiology 162:307-310, 1987.

• 3) Cacciatore B, Lehtovirta P, Wahlstrom T, et al:Preoperative sonographic evaluation of endometrial cancer. Am J Obstet Gynecol 160:133-137, 1989.
  pubmed

• 4) Cacciatore B, Lehtovirta P, Wahlstrom T, et al:Contribution of vaginal scanning to sonographic evaluation of endometrial cancer invasion. Acta Oncologica 28:585-588, 1989.
  pubmed

• 5) Gordon AN, Fleisher AC, Reed GW:Depth of myometrial invasion in endometrial cancer-; Prospective assessment by transvaginal ultrasonography, Gynecologic Oncology 39:321-327, 1990.

• 6) Lehtovirta P, Cacciatore B, Ylostalo P:Serum CA 125 levels and sonography in the preoperative assessment of myometrial invasion of endometrial cancer. British Journal of Obstetrics and Gynecology 101 (June):532-535, 1994,

P.107 掲載の参考文献

• 1) 西谷 巌, 松田壮正:子宮体癌と腫瘍マーカー. 産婦治療 64:454-457, 1992.

• 2) 根岸能之:婦人科悪性腫瘍における新しい腫瘍マーカーCytokeratin 19の臨床的有用性に関する研究. 臨婦産 47:781-786, 1993.

• 3) 西村隆一郎, 小林 潔, 勝野 誠ほか:尿中β-core fragmentの存在様式に関する基礎的検討とその測定系の確立. 日産婦誌 42:143-148, 1990.

• 4) 石井 勝ほか:Basic fetoprotein EIAキットの臨床的検討 (1) 血清BFPの臨床的有用性. 癌と化学療法 15:2107-2113, 1988.
  Medical*Online

• 5) 稲葉憲之:各領域における腫瘍マーカーの利用の実際婦人科. 図説臨床「癌」シリーズNo 25, 腫瘍マーカー, 山村雄一ほか編, pp 165-169, メジカルビュー社, 東京, 1988.

• 6) 弓立 環, 高山雅臣, 鈴木良知ほか:新しい腫瘍マーカーとしての尿中 hCG β-core fragment (β-CF) 測定の評価. 産と婦 58:1357-1362, 1991.

• 7) Soper T, Berchuck A, Olt GJ, et al:Preoperative evaluatlon of serum CA125, TAG 72, and CA15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 163:1204-1209, 1990.

• 8) Panici PB, Scambaia G, Baiocchi G, et al:Multiple serum markers in patients with endometrial cancer. Gynecol Obstet Invest 27:208-212, 1989.

• 9) Kenemans P, Yemada CA, Bon GG, et al:CA125 in gynecologlcal pathology-a review. Eur J Obstet Gynecol Reprod Biol 49:115-124, 1993.

• 10) Leminen A:Tumor markers CA125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. Gynecol Oncol 39:358-363, 1990.
  pubmed

• 11) Homesley HD, Zaino R:Endometrial cancer:Prognostic factors, Semin Oncol 21 (1):71-78, 1994
  pubmed

• 12) Takeshima N, Shimizu Y, Umezawa S, et al:Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma, Gynecol Oncol 54 (3):321-326, 1994.
  pubmed

• 13) Patsner B:Tumor markers in gynecologic oncology, In:Textbook of gynecology (ed by LJ Copeland) , pp 941-958, WB Saunders Company, PA, USA, 1993.

• 14) Halila H, Alfthan H, Stenman U-H:Clinical use of gynecologic tumor marker. Ann Chir Gynaecol 78 (1):65-70, 1989.
  pubmed

• 15) Gadducci A, Ferdeghini M, Prontera C, et al:A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma. Eur J Gynaecol Oncol 11(4):283-288, 1990,
  pubmed

• 16) 佐藤賢次郎, 水内英充, 森 泰宏ほか:閉経後子宮体癌におけるCA125値測定の有用性につ いての検討. Oncology & Chemotherapy 9 (3):275-279, 1993.

• 17) 野澤志朗, 宇田川康博, 塚崎克己ほか:子宮体癌と腫瘍マーカー-免疫組織化学的染色結果を中心に-. 病理と臨床 7 (1):45-56, 1989.

• 18) Heyderman E, Strudly I, Powell G, et al:A new monoclonal antibody to epithelial membrane antigen (EMA) E 29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2, Brit J Cancer 52:355-361, 1985.

• 19) Nozawa S, Sakayori M, Ohta K, et al:A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line(SNG-II) and its application to immunohistochemistry and flow cytometry, Am J Obstet Gynecol 161:1079-1086, 1989.
  pubmed

• 20) Iwamori M, Sakayori M, Nozawa S, et al:Monoclonal antibody-defined antigen of human uterine endometrial adenocarcinoma is Leh. J Biochem 105:718-722, 1989.

• 21) 塚崎克己:子宮体癌の発生に伴う複合糖質発現異常に関する基礎的研究とその臨床へのフィードバック. 日産婦誌45:789-801, 1993.

• 22) 塚崎克己, 吉田憲一, 木挽貢慈ほか:婦人科がん検診の現況と展望II. 子宮体癌検診4. 腫瘍マーカー. 産と婦61:947-954, 1994.

• 23) 野澤志朗, 佐久間達朗, 太田邦彦ほか:子宮体癌における腫瘍関連抗原の発現. 日本婦人科病理・コルポスコピー学会誌7 (2):160-167, 1989.

• 24) 塚崎克己, 堀江昭子, 酒依元子ほか:子宮体癌の新しい補助診断法 (EmC-EIA法) の開発とその有用性に関する検討. 第11回腫瘍マーカー研究会誌pp 101-104, 1991.

• 25) 塚崎克己, 久布白兼行, 佐久間雄一 ほか:子宮体癌と複合糖質. 図説産婦人科view 27分子生物学 (川名 尚, 野澤志朗編), pp 106-117, メジカルビュー社, 1997.

• 26) 久布白兼行, 塚崎克己, 佐久間雄一ほか:子宮体癌におけるMSN-1認識抗原の組織接着ならびに転移に与える影響. 日産婦誌47 (2):163-164, 1995.

• 27) Sasano H, Watanabe K, Ito K, et al:New concepts in the diagnosis and prognosis of endometrial carcinoma, Pathol Annu 29:31-49, 1994.
  pubmed

• 28) 森 崇英:婦人科学-婦人科癌における遺伝子変異と診断・治療への応用 .日本医事新報, 3694:31-34, 1995.

• 29) 村瀬隆之, 今村利朗, 有馬隆博ほか:癌と遺伝子の話題. 産婦実際44:49-54, 1995.

• 30) Jones MH, Nakamura Y:Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms, Oncogene 7:1631-1634, 1992.
  pubmed

• 31) Imamura T, Arima T, Kato H, et al:Chromosomal deletions and K-ras gcne mutations in human endometrial carcinomas. Int J Cancer 51:47-52, 1992.

第3章 進行期分類

P.115 掲載の参考文献

• 1) 日本産科婦人科学会ほか編:子宮体癌取扱い規約. pp 5-9, 金原出版, 東京, 1996.

• 2) FIGO News:Int J Gynecol Obstet 28:189-193, 1989.

• 3) 末舛恵一:監修, 柄川 順編集:最新TNMアトラス. pp 224-229, シュプリンガー・フェアラーク, 東京, 1991.

• 4) Creasman WT, et al:Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intra-peritoneal radiopharmanceuticals. Am J Obstet Gynecol 141:921-927, 1981.
  pubmed

• 5) Mazurka JL, et al:Prognostic significance of positive peqritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol 158:303-306, 1988.
  pubmed

• 6) Hermandez E, et al:Peritoneal cytology in stage I endometrial cancer. J Natl Med Assoc 77:799-803, 1985.

• 7) 矢島正純ほか:子宮体癌の新しい進行期分類における予後の検討. 臨婦産47:1460-1462, 1993.

• 8) 嘉村敏治ほか:子宮体癌の新しいFIGO臨床進行期分類 (1988) について-現行の日産婦分類との比較-. 産と婦9:1873-1842, 1990.

第4章 治療

P.128 掲載の参考文献

• 1) 前田隆義, 植木 實, 岡村信介ほか:子宮体癌所属リンパ節の郭清・転移に関する臨床的検討. 産婦の進歩44:189-196, 1992.

• 2) Creasman WT, et al:Surgical spread patterns of endometrial cancer. Cancer 60:2035, 1987.
  pubmed

• 3) 福井秀樹, 多田克彦, 関場 香:体癌におけるリンパ節の取り扱い. 産と婦9:1597-1601, 1987.

• 4) Wallin TE, et al:Stage II cancer of the endometrium; A pathologic and clinical study. Gynecol Oncol 18:1-17, 1984.
  pubmed

• 5) 宇田川康博, 宮下明子, 伊藤高太郎ほか:子宮体癌の手術後治療の問題点-術後治療と予後-, 産と婦 9:1307-1311, 1992.
  Medical*Online

P.135 掲載の参考文献

• 1) Taghian A, Pernot M, Hoffstetter S, et al:Radiationtherapy alone for medicallyin operatlve patients with adenocarclnoma of the endometrium. Int J Radiat Oncol Biol Phys 15:1135-1140, 1988.

• 2) Rotman M. Aziz H, Halpern J, et al:Endometrial carcinoma. Influence of prognostic factors on radiation management. Cancer 71(supple):1171-1179, 1993.

• 3) Greven KM, Lanciano RM, Herbert SH, et al:Analysis of complications inpatients with endometrial carclnoma receiving adjuvant irradiation. Int J Radiat Oncol Biol Phys 21:919-923, 1991.

• 4) Aslders JG, Syde RVD, Poppema S, et al:Prognostic factors and changing trends in the treatment of stage I endometrial cancer; Clinical and histopathological study of 182 patients. Int J Radiat Oncol Biol Phys 1O:2083-2088, 1984.

• 5) DiSaia PJ, Creasman WT, Boronow RC, et al:Risk factors and recurrent patients in stage I endometnal cancer. Am J Obstet Gynecol 15:1009-1015, 1985.

• 6) Schray MA, Podratz M, Stanhope R, et al:Postoperative whole abdominopelvic irradiation for patients with high risk endometrial cancer. Int J Radiat Oncol Biol Phys 17:317, 1989.

• 7) Gibbons S, Martinez A, Achray M, et al:Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys 21:1019-1025, 1991,

• 8) Corn BW, Lanciano RM, Greven KM, et al:Endometrial cancer with para-aortic adenopathy; Patterns of failure and opportunities for cure. Int J Radiat Oncol Biol Phys 24:223-227, 1992.
  pubmed

• 9) Rose PG, Cha SD, Rak WK, et al:Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys 24:229-233, 1992.

• 10) Kim YB, Niloff JM:Endometrial carcinoma; Analysis of recurrence in patients treated with a strategy minimizing lymph node sampling and raddiation therapy, Obstet Gynecol 82:177-180, 1993.

• 11) Huguenin PU, Glanzmann C, Hammer F, et al:Endometrial carcinoma in patients aged 75 years or older; Outcome and complications after postoperative radiotherapy or radiotherapy alone. Strahlenther Onkol 168:567-572, 1992,

• 12) Higgins RV, van Nagell JR Jr, Horn EJ, et al:Preoperative radiation therapy followed by extrafascial hysterectomy in patients with stage II endometrial carcinoma. Cancer 68:1261-1264, 1991.
  pubmed

• 13) Horowich A:Combined radiotherapy-chemotherapy in clinical practice. (In) The biological basis of radiotherapy, pp 279-289, (eds) Steel GG, Adams GE, Horowich A, Amsterdam, 1989.

• 14) Glastein E, Fuks Z, Bagshaw MA:Diaphragmatic treatment in ovarian carcinoma; a new radiotherapeutic technique, Int J Radiat Oncol Biol Phys 2:357-362, 1977.

• 15) Martinez A, Schray MF, Howes AE, et al:Postoperative radiation therapy for epithelial ovarian cancer; The curative role based on a 24-year experience. Clin Oncol 3:901-911, 1985.
  pubmed

• 16) Yong RC, Fuks Z, Hoskins WJ:Cancer of the ovary. (In) Cancer, Principles & Practice of Oncology (3rd ed), pp 1174-1177, Devita VT, Hellman S, Rosenberg SA.1989,

• 17) Dembo AJ:The Ovary. (In) Radiation Oncology (6th ed), pp 586-593, Moss WT & Cox JD (eds), Mosby, 1989.

• 18) Heyman J:The Radiumhemmet method of treatment and results in cancer of the uterus. Br J Obstet Gynecol 43:655-665, 1936.

P.149 掲載の参考文献

• 1) Ahmad K et al:Radiotherapy in stage II carclnoma of the endometrium Cancer 63:354-358, 1989.

• 2) 山本 宝:子宮体癌up date; 治療-ホルモン, 抗癌化学療法-. 産と婦35:865-870, 1995.

• 3) 加藤 俊ほか:卵巣癌に対するcarboplatinの第II相試験. 癌と化学療法15:2291-2296, 1988.

• 4) 塚本直樹ほか:新しいAnthnacycline系抗癌剤Epirublcinの悪性卵巣腫瘍に対する治療効果-共同研究によるphase II study-. 薬剤の臨床53:1611-1615, 1986.

• 5) 牧野浩充ほか:進行・再発子宮体癌の化学療法. Oncology & Chemotherapy 8:37-43, 1992.

• 6) Thigpen T, et al:A randomized comoarison of the adriamycin with of advanced or recurrent endometrial carcinoma. Proc Am Soc Clin Oncol 4:115, 1985.

• 7) Burke TW, et al:Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide, Gynecol Oncol 40:264-267, 1991.

• 8) Edmonson JM, et al:Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patlents with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 28:20-24, 1987.

• 9) 栗原操寿ほか:子宮体がん第1次研究, 子宮体がん第2次研究. Oncology & Chemotherapy 5:171-177, 1989.

• 10) 川越 厚:子宮頸癌, 子宮体癌に対する内腸骨動脈化学療法の治療成績. 日癌治誌 24:765-771, 1989.

• 11) 山田龍作ほか:新しい抗癌剤投与法-Ballon catheterによる一時的動脈閉塞下抗癌剤動注法の開発-. 日医放会誌41:894, 1981.

• 12) 高野 敦ほか:進行子宮体癌に対する抗癌剤動注(BOAI)療法の検討. Oncology & Chemotherapy 3:338-344, 1987.

• 13) 寺島芳樹ほか:産婦人科悪性腫瘍化学療法時の好中球減少に対するrecombinant human G-CSF (rG-CSF注) の臨床的有用性の検討. 日癌治誌25:1461-1471, 1990.

• 14) Biesma B, et al:Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80:1141-1148, 1992.
  pubmed

• 15) 宇田川康博, 野澤志朗:子宮体癌の予後因子からみた治療法の選択. 日本外科系連合会誌 25:33-36, 1993.

• 16) 可世木博, 水野一夫, 井上武夫ほか:子宮体癌の手術後治療の問題点-III期子宮体癌の術後治療の問題点-. 産と婦59:1312-1316, 1992.

• 17) 早川清一朗, 佐藤信二, 高野忠夫ほか:子宮体癌に対する化学療法. 癌と化学療法22:1169-1175, 1995.

• 18) 宇田川康博, 小室優貴, 青木大輔ほか:子宮体癌の手術術式および術後療法の選択. 第33回日本癌治療学会総会Educational Book pp 405-408, 1995.

• 19) 竹島信宏, 清水敬生, 梅沢 聡ほか:子宮体癌の化学療法. 産婦治療67:124-128, 1993.

• 20) 鹿沼達哉ほか:子宮体癌の化学療法・ホルモン療法. 癌の臨床36:1161-1165, 1990.

• 21) 栗原操寿ほか:子宮内膜癌に対するMedroxy-progesterone acetate (MPA) の治療効果に関する検討-子宮内膜癌に対するMPA療法研究会-. 産婦実際34:517-538, 1985.

• 22) Carlson J, et al:Tamoxifen and endometrial carcinoma; Alterationin estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neo-plasin. Am J Obstet Gynecol 149:149-153, 1984.

• 23) Kullander S:Treatment of endometrial cancer with GnRH analogs. Recent Results in Cancer Research 124:69, 1992.
  pubmed

• 24) 岡田弘二ほか:子宮体癌に対するadriamycin, MPA (medroxyprogesterone acetate) 併用療法の効果. 産と婦57:258-263, 1990.

• 25) 宮崎康二, 岡村 均:非特異的免疫療法を併用した免疫化学療法による予後改善. 産婦世界 48:55-61, 1996.

P.153 掲載の参考文献

• 1) 宇田川康博, 宮下明子, 野澤志朗:若年性子宮体癌の病態と治療の特徴. KARKINOS 6 (7):735-738, 1993.

• 2) 宇田川康博, 野澤志朗:子宮体癌の予後因子からみた治療法の選択. 日本外科系連合誌25:33-36, 1992.

• 3) 藤本征一郎, 西谷雅史, 桜木範明ほか:旁大動脈リンパ節転移と子宮体癌の予後との関連について. 産婦実際40 (2):237-244, 1991.

• 4) 矢嶋 聰, 野澤志朗:子宮体がん委員会-第4次研究-. 婦人科がん化学療法共同研究会化療ニュース3 (4):8-9, 1995.

第5章 治療成績

P.168 掲載の参考文献

• 1) FIGO News:Int J Gynecol Obstet 28:189493, 1989.

• 2) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会編:子宮体癌取扱い規約. 1996年3月[改訂第2版], 金原出版, 東京, 1996.

• 3) 日本産科婦人科学会婦人科腫瘍委員会:第33回治療年報. 日産婦誌47 (3):299-365, 1995.

• 4) 日本産科婦人科学会子宮癌登録委員会:全国子宮体癌調査成績. 第3報, 1984.

• 5) Wallin TE, Malkasian GD Jr, Gaffey TA, et al:Stage H cancer of the endo-metrium; A pathologic and clinical study. Gynecol Oncol 18:1-17, 1984,

• 6) 井上正樹:子宮体癌の予後. 産と婦 60 (増刊):214-217, 1993:

• 7) 日本産科婦人科学会子宮癌登録委員会:全国子宮体癌調査成績. 第1報, 1980.

• 8) FIGO:Annual report on the results of treatment in gynecological cancer, Vol 18, 1982,

• 9) Petterson F:Annual report on the results of treatment in gynecological cancer (Vol 21). lnt J Gynecol Obstet 36 (supple):132-237, 1991,

• 10) 宇田川康博, 野澤志朗:婦人科癌の外科的治療-子宮体癌の予後因子からみた治療法の選択.日本外科系連合会誌25:33-36, 1992.

• 11) 宇田川康博, 宮下明子, 伊藤高太郎, 野澤志朗:子宮体癌の手術後治療の問題点-術後治療と予後-. 産と婦59:1307-1311, 1992.

• 12) Onsrud M, Kolstad P, Normann T:Postoperative external pelvic irradiation in carcinoma of the corpus stage I; a controlled clinical trial. Gynecol Oncol 4 (2):222-231, 1976.

• 13) 藤本征一郎, 西谷雅史, 桜木範明ほか:傍大動脈リンパ節転移と子宮体癌の予後との関連について. 産婦実際40 (2):237-244, 1991.

• 14) 野澤志朗, 宇田川康博:第13回婦人科がん化学療法共同研究会総会記録, 子宮体がん委員会-第4次研究について . Oncol & Chemother 12 (Supple):21-24, 1996.

• 15) 栗原操寿ほか:子宮内膜癌に対するMedroxy progesterone acetate (MPA) の治療効果に関する検討-子宮内膜癌に対するMPA療法研究会. 産婦実際34 (4):517-536, 1985.

• 16) 蔵本博行, 上坊敏子, 秦 宏樹ほか:子宮体癌に対するホルモン療法の展望. 産と婦61 (9):1269-1274, 1994.

• 17) 蔵本博行, 上坊敏子, 大河原聡:若年体癌の諸問題. 産と婦55 (9):1703-1710, 1988.

• 18) 山川義寛,:下井康夫, 中山一武ほか:若年性子宮体癌の臨床病理学的検討. 日産婦誌43 (1):45-50, 1991.

• 19) Silverberg SG:The disease in young women. In Endometrial carcinoma and its treatment III (ed by Gray LA, Thomas CC), Springfield, 1977.

• 20) 加藤久盛, 荒木 勤:若年性体癌の問題点. 産婦実際37 (6):877-880, 1988.

• 21) 宇田川康博, 宮下明子, 野澤志朗:若年性子宮体癌の病態と治療の特徴. KARKINOS 6:735-738, 1993.

• 22) 蔵本博行:予後因子からみた治療法の選択. 図説産婦人科VIEW 10. 腫瘍-治療法の選択-. pp 50-61, メジカルビュー社, 東京, 1994.

• 23) Creasman WT, Soper JT, McCarty KS Jr, et al:Influence of cytoplasmic s teroid receptor content on prognosis of early stage endometrial carcinoma, Am J Obstet Gynecol 151 (7):922-932, 1985.

• 24) Kauppila AJ, Isotalo HE, Kivinen ST, et al:Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 46 (10):5380-5384, 1986.
  pubmed

• 25) 加藤順三:子宮体癌と乳癌の共通点と相違点-主として内分泌学的観点から-. 産と婦61 (9):1233-1239, 1994.

• 26) Cancer mortality and morbidity statistics:Japan and the world, 1994/edited by Tominaga S, et al. Japan Scientific Societies Press, Tokyo, 1994.

第6章 フォローアップ

P.177 掲載の参考文献

• 1) FIGO News:Corpus cancer staging, Int J Gynecol Obetet 28:189-193, 1989.

• 2) 宇田川康博, 野澤志朗:子宮体癌の予後因子からみた治療法の選択. 日外科系連会誌25:33-36, 1992.

• 3) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会編:子宮体癌取扱い規約. 金原出版, 東京, 1987.

• 4) Lehderman GS, Niloff JM, Redline R, et al:Late recurrence in endometrial carcinoma. Cancer 59:825-828, 1987

P.192 掲載の参考文献

• 1) VAN Keep PA, Kellerhals J:The ageing women. Ageing and estrogens. Front Hormone Res 2:160-173, 1973.

• 2) Utian WH:Menopause in modern perspective. A guide to clinical practice. p 108, Appleton Century Crofts, New York, 1980.

• 3) 太田博明, 隅田能雄, 牧田和也ほか:閉経と脂質リポ蛋白代謝-閉経後の期間および年齢に伴う変化-. 日更年医誌 1:80-85, 1993.

• 4) Suda Y, Ohta N, Nakita K, et al:Influence of bilateral oophorectomy upon lipid metabolism. Maturitas 29:147-154, 1998.

• 5) Kannel WB, Castelli WP, Gordon T, et al:Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 74:1-12, 1971.
  pubmed

• 6) 厚生省特定疾患, 原発性高脂血症調査研究班, 平成6年度研究報告書. 1995.

• 7) Martin MJ, Hulley SB, Browner WS, et al:Serum cholesterol, blood pressure, and mortality; implications from a cohort of 361, 662men. Lancet 2:933-936.1986,
  pubmed

• 8) Lipid Research Clinics Program:The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251:351-364, 1984.

• 9) Frick MH, Elo O, Haapa K, et al:Helsinki Heart Study; primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245. 1987.
  pubmed

• 10) Ohta H, Komukai S, Sugimoto I, et al:Effect of a HMG-CoA reductose inhibitor combined with hormone replacenlent therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia:amulticenter double-blind controlled prospective study. Maturitas 29:163-171, 1998.

• 11) Ross RK, Pike MC, Henderson BE, et al:Stroke prevention and oestrogen replacement therapy. Lancet 1:505, 1989.
  pubmed

• 12) Meade TW, Berra A:Hormone replacement therapy and cardiovascular disease. Br Med Bull 48:276-308, 1992.
  pubmed

• 13) 太田博明, 池田俊之, 増沢利秀ほか:本邦婦人におけるホルモン補充療法の臨床的効果と good responderの選別. 産婦治療68:491, 1994.

• 14) Tikkanen MJ, Kuusi T, Nikkila EA, et al:Post-menopausal hormone replacement therapy; effect of progestogens on serum lipids and lipoproteins. A review. Maturitas 8:7-17, 1986.
  pubmed

• 15) Munk-Jensen N, Ulrich LG, Obel EB, et al:Continuous combined and sequential estradiol and norethindrone acetate treatment of postmenopausal women; effect on plasma lipoproteins in a two-year placebo-controlled trial. Am J Obstet Gynecol 171:132-138, 1994.

• 16) Lobo RA:Clinical review 27. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73:925-930, 1991,
  pubmed

• 17) The Expert Panel:Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 148:36-69, 1988,

• 18) Richelson LS, Wahner HW, Melton LJ III, et al:Relative contributions of aging and estrogen deficiency to postmenopausal bone loss, N Engl J Med 311:1273-1275, 1984.

• 19) Ohta H, Ikeda T, Masuzawa T, et al:Differences in axial bone mineral density, serum levels of sex steroids, and bone metabolism between postmenopausal and age-and body size-matched premenopausal sublects, Bone 14:111-116, 1993.

• 20) 太田博明, 増田あさ子:s小武海成之ほか:閉経後および卵摘後骨粗霧症. 日臨52:2382-2394, 1994.

• 21) Ohta H, Makita K, Suda Y, et al:Influence of oophorectomy on serum levels of sex steroids and bone metabolism and assessment of bone mineral density in lumbar trabecular bone by QCT-C value. J Bone Miner Res 7:659-665, 1992.
  pubmed

• 22) 太田博明:更年期と骨-ヒト臨床例における閉経による変化を中心に-. ホと臨床42:457-468, 1994.

• 23) Pacifici R, Rifas L, McCracken R, et al:Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin-1 release. Proc Natl Acad Sci USA 86:2398-2402, 1989.
  pubmed

• 24) Pacifici R, Brown C, Puscheck E, et al.:Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 88:5134-5138, 1991.
  pubmed

• 25) Aitken JM, Hart DM, Lindsay R:Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J 3:515-518, 1973.
  pubmed

• 26) Genant HK, Baylink DJ, Gallagher JC:Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol 161:1842-1846, 1989.
  pubmed

• 27) Nachtigall LE, Nachtigall RH, Nachtigall RD, et al:Estrogen replacement therapy II; a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54:74-79, 1979.

• 28) Lindsay R:Sex steroids in the pathogenesis and prevention of osteoporosis. In; Riggs BL, Melton LJ III, eds. Osteoporosis; Etiology, diagnosis and management. pp 333-358, New York, Raven Press, 1988,

• 29) Flecher CD, Farish E, Leggate J, et al:Prevention of bone loss by hormone rcplacement therapy is probably not due to stimulation of calcitonin secretion. Acta Endocrinol Copenh 124:353-356, 1991.

• 30) Ettinger B, Genant HK, Cann CE:Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 106:40-45, 1987,
  pubmed

• 31) McNeeley SG Jr, Schinfeld JS, Stovall TG, et al:Prevention of osteoporosis by medroxyprogesterone acetate in postmenopausal women, Int J Gynecol Obstet 34:253-256, 1991,

• 32) Lindsay R, Hart DM, MacLean A, et al:Bone response to termination of oestrogen treatment. Lancet 1:1325-1327, 1978.
  pubmed

• 33) Horsman A, Gallagher JC, Simpson M, et al:Prospective trial of oestrogen and calcium in post. menopausal women. Br Med J 2:789-792, 1977.

• 34) Christiansen C, Christiansen MS, Transbol I:Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy, Lancet 1:459-461, 1981.

• 35) Grady D, Rubin SM, Petitti DB, et al:Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037, 1992.
  pubmed

• 36) Mack TM, Pike MC, Henderson BE, et al:Estrogens and endometrial cancer in a retirement community, N Engl J Med 294:1262-1267, 1976,

• 37) Buring JE, Bain CJ, Ehrmann RL:Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 124:434-441, 1986.
  pubmed

• 38) Kennedy DL, Baum C, Forbes MB:Noncontraceptive estrogens and progestins; use patterns over time. Obstet Gynecol 65:441-446, 1985.
  pubmed

• 39) Chu J, Schweid AI, Weiss NS:Survival among women with endometrial cancer; a comparison of estrogen users and nonusers, Am J Obstet Gynecol 143:569-573, 1982.
  pubmed

• 40) Ettinger B, Golditch IM, Friedman G:Gynecologic consequences of long-term, unopposed estrogen replacement therapy. Maturitas 10:271-282, 1988.
  pubmed

• 41) Gambrell RD Jr, Massey FM, Castaneda TA, et al:Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 55:732-738, 1980,
  pubmed

• 42) Voigt LF, Weiss NS, Chu J, et al:Progestagen supplementation of exogenouse oestrogens and risk of endometrial cancer. Lancet 338:274-277, 1991,

• 43) Whitehead MI, Fraser D:The effects of estrogens and progestogens on the endometrium. Modern approach to treatment. Obstet Gynecol Clin North Am 14:299-320, 1987.
  pubmed

• 44) Thom MH, White PJ, Williams RM, et al:Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy, Lancet 2:455-457, 1979.
  pubmed

• 45) American College of Physicians:Guidlines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 117:1038-1041, 1992.

• 46) Beresford SAA, Weiss NS, Voigt LF, McKnight B:Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progcstagen therapy in postmenopausal women. Lancet 349:458-461, 1997.

• 47) Creasman WT, Henderson D, Hinshaw W, et al:Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67:326-330, 1986.
  pubmed

• 48) Lee RB, Burke TW, Park RC:Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36:189-191, 1990.

第7章 新しい展開

P.219 掲載の参考文献

• 1) Mayer A, Heim K:Uber Gewebezuchtang. Zentralbl Gynakol 50:2688-2689, 1926.

• 2) 野嶽幸雄:産婦人科領域における組織培養応用の研究図譜. 第15回日本産婦人科学会総会宿題 報告, 1963.

• 3) Gey GO, Coffman WD, Kubicken MT:Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium, Cancer Res 12:264-265, 1952.

• 4) Kuramoto H, Tamura S, Notake Y:Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 114:1012-1018, 1972.
  pubmed

• 5) 石川 博:現代病理学大系16A (飯島宗一, 石川英世ら編)-女性性器の発生. pp 161-200, 中山書店, 東京, 1994.

• 6) Page DC, Mosher R, Simpson EM, et al:The sex-determing region of the human Y chromosome encordes a finger protein. Cell 51:1091-1104, 1987.

• 7) Jost A:Recherches sur la differenciation sexulle de lembyon de lapin. Arch Anat Micros Morphol Exp 36:271-315, 1947.

• 8) Cohen-Haguenauer O, Picard JY, Mattei MG, et al:Mapping of the gene for anti-Mullerian hormone to the short arm of human chromosome 19. Cytogenet Cell Gent 44:2-6, 1987.

• 9) Dawe CJ, Banfield WG, Morgan WD, et al:Growth in continuous culture, and in hamsters, of cells from a neoplasma associated with acanthosis nigricans. J Natl Cancer Inst 33:441-456, 1964.

• 10) Kuramoto H, Hamada M:Establishment and charactelization of the cell-line of human endometrial adenocarcinoma. Europ-J Cancer 13:253-259, 1977.

• 11) Ishiwata L Nozawa S, Inoue T, et al:Development and characterization of estabhished cell lines from primary and metastatic regions of human endometrial adenocarcinoma. Cancer Res 37:1777-1785 1977.

• 12) 蔵本博行, 浜野美恵子, 西田正人ほか:腹水由来子宮体癌細胞株の樹立. 日産婦誌28:1405-1406, 1976.

• 13) Merenda C, Soedat B, Mach JP, et al:Human endometrial carcinomas serially transplanted in nude mice and established in continuous cell lines. Int J Cancer 16:559-570, 1975.

• 14) Gorodecki J, Mortel R, Ladda RL, et al:Establishment and characterization of a new endometrial cancer cell line (SCRC-1). Am J Obstet Gynecol 135:671-679, 1979.
  pubmed

• 15) 森沢隆行:子宮体癌の初代培養成績と樹立細胞株の諸性格. 日臨細胞誌26:433-442, 1987.

• 16) Yasui Y:Establishment and characterization of the cell-line of a human endometrial carcinoa. Acta Obst Gynaec Jpn 39:297-302, 1987.

• 17) 西田正人, 笠原国武, 金子実ほか:エストロゲン, プロゲステロンレセプターを持つヒト分化型子宮体内膜腺癌株 (Ishikawa株) の樹立. 日産婦誌37:1103-1111, 1985.

• 18) Ishiwata I, Ishiwata C, Nozawa S, et al:Biological characteristics of cultured endometrial adenocarcinoma cells and changes in their characteristics following serial passage. Asia-Oceania J Obstet Gynecol 12:433-442, 1986.

• 19) Ishiwata I, Ishiwata C, Nozawa S, et al:Establishment of human endometrial adenocarcinoma cell line containing estradiol-17β and progesterone receptors. Gynecol Oncol 17:281-290, 1984.

• 20) Ono I, Ishiwata I, Tashiro A, et al:Establishment and characterization of two human mixed mesodermal tumor cell lines from the same patient. J Nat Cancer Inst 72:1241-1252, 1984.

• 21) Ishiwata I, Ishiwata C, Soma M, et al:Histogenesis and tissue reconstruction of mixed mesodermal tumor. Exp Pathol 30:21-32, 1986.
  pubmed

• 22) Nozawa S, Sakayori M, Ohta K, et al:A monoclonal antibody (MSN-I) against a newly established uterine emdometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry. Am J Obstet Gynecol 161:1079-1086, 1989.

• 23) Gal D, Poter FJ, Den VG, et al:A new human cell line derived from a poorly differentiated endometrial adenocarcinoma. Gynecol Oncol 13:50-57, 1982.

• 24) Ishiwata I, Ishiwata C, Nagayama T, et al:Histogenesis and culture of human uterine carcinoma. Cancer Res 41:1978-1983, 1981.
  pubmed

• 25) Ishiwata L Soma M, Ono L et al:Biological characteristics of adenocarcinoma cell line (HOUA-1) and B lymphoblastoid cell line (HOUA-II) established from the same tissue of endometrial adenocarcinoma. Jikeikai Med J 36:303-315, 1989.

• 26) Way DL, Grosso DS, Davis JR, et al:Characterization of a new human endometrial carcinoma (RL 95-2) established in tissue culture. In Vitro 19:147-158, 1983,

• 27) 三沢芳夫:同一患者より樹立した子宮内膜癌細胞株3種の細胞学的性状とそのhistrogeneityに関する解析. 日産婦誌40:1439-1446, 1988.

• 28) Richardson GS, Dickersin GR, Atkins L, et al:KLM; A cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol Oncol 17:213-230, 1984.

• 29) 森澤孝行, 蔵本博行, 下田隆夫ほか:子宮体部低分化型腺癌由来HEC-108株の樹立経過とその諸性格. Human Cell 1:332, 1988.

• 30) 片岡明生, 神代正道, 中島敏郎ほか:分化型腺癌と明細胞癌の混在する子宮内膜腺癌より分離し得た培養細胞株 (KCC-la, KCC-lb) の樹立. 日本病理誌75:544-545, 1986.

• 31) Yamada T, Ueda M, Maeda T, et al:Establishment and characterization of CA125 producing cell line (OMC-2) originating from a human endometrial adenocarcinoma. Asia-Oceania J Obstet Gynaecol 15:403-416, 1989,

• 32) Boyd JA, Singel GP, Kaufman DG:Establishment and characterization of a human cell line from aserous papillary endometrial adenocarcinoma. Gynecol Oncol 33:301-312, 1989.

• 33) Grenman SE, Worshan MJ, Van Dyke DL, et al:Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line. Gynecol Oncol 37:188-199, 1990.

• 34) 石渡 勇, 相馬雅行, 石川 博:子宮体部中胚葉性混合腫瘍由来肉腫培養細胞株(HTMMT)の樹立とその性状. Human Cell 7:46, 1994.

• 35) 石渡 勇, 相馬雅行, 石川 博:低分化型子宮体内膜腺癌細胞株の樹立とその性状. Human Cell 7:47, 1994.

• 36) Ishiwata L lshiwata C, lshikawa M:Effects of estradiol-17β and progesterone on cell proliferation and differentiation of the human endometrial carcinoma cell line (HHUA) in vitro. Asia-Oceania J Obstet Gynaecol 10:531-538, 1984.

• 37) Ishiwata L Udagawa Y, Okumura H, et al:Effects of progesterone on human endometrial carcinoma cells in vivo and in vitro. J Natl Cancer Inst 60:947-954, 1978.

• 38) Ishiwata I, Ishiwata C, Nozawa S, et al:An analytic cellular evaluation of aspirated smears from transplanted human endometrial adenocarcinoma in nude mice treated with 17β-estradiol and progesterone. ACTA Cytologica 26:251-258, 1982.

• 39) Ishiwata L Nozawa S, Okumura H:Effects of 17β-estradiol and progesterone on growth and morphology of human endometrial carcinoma cells in vitro. Cancer Res 37:4246-4249, 1977.

• 40) 秦 宏樹, 秦 和子, 浜野美恵子ほか:子宮内膜癌のステロイドホルモン感受性とその作用機序. Human Cell 2:265-271, 1989.

• 41) Holinka CF, Hata H, Kuramoto H, et al:Effects of steroid hormones and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishikawa line). Cancer Res 46:2771-2774, 1986.
  pubmed

• 42) Holinka CF, Hata H, Kuramoto H, et al:Response to estradiol in human endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem 24:85-89, 1986.

• 43) Hata H, Kuramoto H:Immunocytochemical determination of estrogen and progesterone receptors in human endometrial adenocarcinoma cells (Ishikawa cells). J Steroid Biochem Mol Biol 42:201-210, 1992.

• 44) 秦 宏樹, 浜野美恵子, 辻井 篤ほか:子宮体癌細胞のホルモンならびに増殖因子依存性の研究. Human Cell 6:182-187, 1993.

• 45) 山田秀人, 和気徳夫, 藤野敬史ほか:細胞融合を用いた子宮内膜癌化解明へのアプローチ. 日産婦誌41:122-128, 1989.

• 46) Wake N, Yamada H, Fujita H, et al:Isolation of clones resistant to 6-thioguanine and G 418 from HHUA endometrial carcinoma cells and their application to cell hybridization. Cancer Genet Cytogenet 49:117-123, 1990,

• 47) 佐藤文三:受容体の構造と機能. 実験医学5:26-31, 1987,

• 48) 佐藤文三:ステロイドホルモンレセプター機構. 代謝23:343-348, 1986.

• 49) Nishii H, Risinger JI, Sasaki H, et al:Progesterone receptor gene alterations in endometrial carcinoma. Proc Am Assoc Cancer Res 34:541, 1993,

• 50) 田村向也:子宮内膜癌におけるエストロゲンおよびプロゲステロンレセプター遺伝子の変異. 日産婦誌45:373, 1993.

• 51) 西井 寛, 佐々木寛, 安田 允:子宮体癌におけるプロゲステロンレセプターの役割. 東京慈恵会医科大学誌109:1163-1166, 1994.

• 52) 塚崎克己:子宮体癌の発生に伴う複合糖質発現異常に関する基礎的研究とその臨床へのフィードバック. 日産婦誌45:789-801, 1993.

• 53) Saga T, Ishiwata L Endo K, et al:An antibody-tumor model for the targeting of CA125-producing gynecologic malignancies. JPn J Cancer Res 81:1141-1148, 1990.

• 54) Kobayashi H, Sakahara H, Saga T, et al:A human/mouse chimeric monoclonal antibody against CA125 for radioimmuno-imaging of ovarian cancer. Cancer Immunol Immunother 37:143-149, 1993.

• 55) Fujita N, Yaegashi N, Ide Y, et al:Expression of CD44 in normal human versus tumor endometrial tissues; possible implication of reduced expression of CD44 in lymphvascular apace in. volvement of cancer cells. Cancer Res 54:3922-3928, 1994.

• 56) Mayer R:Mischgeschwulste des Uterus. In; Handbuch der Speziellen Pathologischen Anatomic und Histologie, ed F HENKE und OLUBARSCH. pp 412-515, Julius SpringerBerlin, 1930.

• 57) Ishiwata I, Ono I, Ishiwata C, et al:Heterotransplantation of mixed mesodermal tumor cells in nude mouse-histology of metastatic foci. Gynecol Oncol 27:189-198, 1987.
  pubmed

P.235 掲載の参考文献

• 1) Barlogie B, Drewinko B, Schumann J, et al:Cellular DNA content as a marker of neoplasia in man. Am J Med 69:195.1980.

• 2) Quillamor RM, Furlong JW, Hoschner JA, et al:Relative prognostic significance of DNA flow cytometry and histologic grading in endometrial carcinoma. Gynecol Obstet Invest 26:332, 1988.
  pubmed

• 3) 野口義夫:フローサイトメトリーの理論.フローサイトメトリーハンドブック (天神美夫, 高橋 学, 野村和弘編). pp 23-56, Science Forum, 東京, 1984.

• 4) 高橋 滋, 太田和雄:定義および原理. フローサイトメトリー (監修:太田和雄, 編集:野村 和弘, 高橋 滋), pp 11-24, 蟹書房, 東京, 1988.

• 5) 高橋 学:フローサイトメトリーの技術-サンプル調整と測定. フローサイトメトリーハンドブック (天神美夫, 高橋 学, 野村和弘編). pp 1044, Science Forum, 東京, 1984.

• 6) Cerra R, Zarbo RJ, Crissman JD:Dissociation of cell from solid tumors. Flow cytometry (Darzynkiewicz Z, Crissman HA, eds), Method in Cell Biology, Vol 33 (Willson L監修), Academic Press Inc, San Diego, 1990.

• 7) Iversen OE, Laerum OD:Trout and salmon erythrocytes and hulnan leukocytes as internal standards for ploidy control in flow cytometry. Cytometry 8:190, 1987,
  pubmed

• 8) 村上知之, 佐々木功典, 荻野哲朗ほか:Flow Cytometryによる細胞核DNA量測定の術中病理診断への応用の試み. 関西フローサイトメトリー研究会機関誌6:23, 1987.

• 9) Taylor IW:Arapid single step staining technique for DNA analysis by flow microfluorimetry. J Histochem Cytochem 28:1021, 1980.

• 10) 佐々木功典:VII. 応用-核DNA解析, 胃癌, 大腸癌. フローサイトメトリー (監修:太田和 雄, 編集:野村和弘, 高橋 滋), pp 352-358, 蟹書房, 東京, 1988.

• 11) 佐々木功典, 田中一成, 荻野哲朗ほか:FCMによるaneuploidyの細胞核検出の限界-マイコンによるシュミレーション. 癌の臨床32:900, 1986.

• 12) Hiddemann W, Schumann J, Andreeff M, et al:Convention on nomenclature for DNA cytometry. Cytometry 5:445, 1984,

• 13) Dean PN:A simplified method of DNA distribution analysis. Cell Tissue Kinert 13:299, 1980.

• 14) Lindahl B, Arm P, Killander D, et al:Flow cytometric DNAanalysis of normal and cancerous human endometrium and cytological-Histopathologic correlations. Anticancer Research 7:781, 1987.

• 15) Tsou K, Hong D, Varello MA, et al:Flow cytometric DNA and 5'-nucleotide phosphodiesterase in endometrium, Cancer 56:2340, 1985.
  pubmed

• 16) Shankey TV, Rabinovitch PS, Bagwell B, et al:Guidelines for Implementation of Clinical DNA Cytometry. Cytometry 14:472-477, 1993.
  pubmed

• 17) Putten HWHMVD, Baak JPA, Koenders TJM, et al:Prognostic value quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 63:1378, 1989.

• 18) 和泉 滋, 山岡完司, 新井宏治ほか:子宮体癌におけるフローサイトメトリーを用いてのDNA解析. 日産婦誌 43 (7):722-728, 1991.

P.245 掲載の参考文献

• 1) Ito K, Sasano H, Watanabe K, et al:Immunohistochemical study of PCNA (Proliferating cell nuclear antigen) in normal and abnormal endometrium, Int J Gynecol Cancer 3:122, 1993.
  pubmed

• 2) Sasano H, Comerford J, Wilkins on DS. et al:Serous papillary adenocarcinoma of the endometrium; Protooncogene amplification, flow cytometry, estrogen and progesterone receptors and immunohistochemical analysis, Cancer 65:1545, 1990,

• 3) Kacinski BM, Carter D, Mittal K, et al:High level expression of fms protooncogene mRNA is observed in clinically aggressive human endometrial adenocarcinoma. Int J Radiat Oncol Biol Phvs 15:823, 1988.

• 4) Long CA, O'Vrien TJ, Sanders MM et al:A ras oncogene is expressed in adenocarcinoma of the endometrium. Am J Obstet Gynecol 159:1512, 1988,

• 5) Brumm C, Riviere A. Wilckiens C, et al:Immunohistochemical investigation and northern blot analysis of c-erb-B2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri, Virchows Arch 417:477. 1990.
  pubmed

• 6) Enomoto T, Inoue M, Perantoru AO, et al:K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 50:6139, 1990.

• 7) Borst MP, Baker VV, Dixon D, et al:Oncogene alterations in endometrial Carcinoma. Gynecol Oncol 38:364, 1990.
  pubmed

• 8) Berchuck A, Rodriguez G, Kamel A, et al:Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15, 1991,

• 9) Sato S, Ito K, Ozawa N, et al:Analysis of point mutation at condon 12 of K-ras in human endometrial carcinoma and cervical adenocarcinoma by dot blot hybridization and polymerase chain reaction. Tohoku J Exp Med 165:131. 1991.

• 10) Sato S, Ito K, Ozawa N, et al:Expression of c-myc. epidermal growth factor receptor and c-erb-B2 in human endometrial carcinoma and cervical adenocarcinoma. Tohoku J Exp Med 165:137, 1991.

• 11) Sato S, Jiko K, Ito K, et al:Expression of c-myc RNA and protein in human endometrial carcinoma; Simultaneous study of in situ hybridization and immumohistochemistry. Tohoku J Exp Med (In press).

• 12) Enomoto T, Inoue M, Perantoru AO, et al:K-ras activation in premalignant and malignant lesions of the human uterus, Cancer Res 51:5301, 1991.

• 13) Hetzel DJ, Wilson TO, Keeney GL, et al:HER-2/neu expression; A major prognosticfactor in endometrial cancel. Gynecol Oncol 47:179, 1992.

• 14) Fujimoto I, Shimizu Y, Hirai Y, et al:Study of ras oncogene activation in endometrial carcinoma. Gynecol Oncol 48:196, 1993.

• 15) Mizuuchi H, Nasim S, Kudo R, et al:Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 52:2777, 1992,
  pubmed

• 16) Sasaki H, Nishii H, Takahashi H, et al:Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma, Cancer Res 53:1906. 1993.
  pubmed

• 17) Enomoto T, Fujita M, Inoue M, et al:Alterations of the p 53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53:1883, 1993,

• 18) Ito K, Watanebe K, Nasim S, et al:K-ras point mutation in endometrial carcinoma; effect on outcome is dependent on age of patient. Gynecol Oncol 63:238, 1996,

• 19) 佐藤信二:癌関連遺伝子. 異常, 細胞増殖および細胞外マトリックスの検索による子宮体癌・子宮内膜増殖症の生物学的悪性度の評価. 日産婦誌45:776, 993.

• 20) Okamoto A, Sameshima Y, Yamada Y, et al:Allelic loss of chromosome 17p and p 53 mutations in human endometrial carcinoma of the uterus, Cancer Res 51:5632, 1991.

• 21) Jones MH, Nakamura Y:Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite pleomorphisms. Oncogene 7:1631, 1992.

• 22) KOhler MF, Berchuck A, Davidoff AM, et al:Overexpression and mutation of p 53 in endometrial carcinoma. Cancer Res 52:1672, 1992.

• 23) Bur ME, Perlman C. Edelmann ?, et al:p 53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 98:81, 1992.

• 24) Jiko K, Sasano H, Ito K, et al:Immunohistochemical and in situ hybridization analysis of p 53 in human endometrial carcinoma of the uterus, Anticancer Res 13:305, 1993,

• 25) Risinger JI, Dent GA, Ignor-Trowbridge D, et al:P 53 gene mutations in human endometrial carcinoma, Mol Carcinog 5:210, 1992,

• 26) Ito K, Watanabe K, Nasim S, et al:Prognostic significance of p 53 overexpression in endometrial cancer. Cancer Res 54:4667, 1994.

P.266 掲載の参考文献

• 1) Koprowski H. et al:Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Geneties 5:957-971, 1979.

• 2) Tsukazaki K, Sakayori M, Arai H, et al:Abnormal expression of blood group-related antigens in uterine endometrial cancers, Jpn J Cancer Res 82:934-941, 1991,
  pubmed

• 3) Nozawa S, Sakayori M, Ohta K. et al:A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry. Am J Obstet Gynecol 161:1079-1086, 1989,
  pubmed

• 4) Iwamori M. Sakayori M, Nozawa S, et al:Monoclonal antibody-defined antigen of human uterine endometrial carcinomas is Leh. J Biochem 105:718-722, 1989.

• 5) 塚崎克己:子宮体癌の発生に伴う複合糖質発現異常に関する基礎的研究とその臨床へのフィードバック. 日産婦誌 45:789-801, 1993.

• 6) Susumu N, Kawakami H, Aoki D, et al:Subcellular localization of blood group Leh antigen (MSN-1-reactive antigen) in endometrial cancer cells. Cancer Res 53:3643-3648, 1993.

• 7) Hartel-Schenk S, Minnifield N, Reutter W, et al:Distribution of glycosyl-transferases among Golgi apparatus subfractions from liver and hepatomas of the rat. Biochem Biophys Acta 1115:108-122, 1991,

• 8) Susumu N. Itoh K, Aoki D. et al:Immunoelectron microscopic studies of ovarian epithelial carcinomas and emdometrial adenocarcinomas using a monoclonal antibody against GAT (galactosyltransferase associated with tumor). J Clin Electron Microscopy 24:781-782, 1991.

• 9) Schnaar R:Glycosphingolipids in cell surface recognition. Glycobiology 5:477-485, 1991,
  pubmed

• 10) Takada A, Ohniori K, Yoneda T, et al:Contribution of Carbohydrate Antigens Sialyl Lewis A and Sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 53:354-361, 1993.
  pubmed

• 11) Kubushiro K, Kojima K, Mikami M, et al:Menstrual cycle-associated alteration of sulfogalactosylceramide in human uterine endometrium. Arch Biochim Biophys 268:129-136, 1989.

• 12) Kubushiro K, Tsukazaki K, Tanaka J, et al:Human Uterine Endometrial Adenocarcinoma; characteristic acquirement of synthetic potentials for II ?SO?-Laccer and ganglio series sulfoglycosphingolipids after transfer of the cancer cells to culture. Cancer Res 52:803-809, 1992.

• 13) Mikami M, Kubushiro K, Tsukazaki K, et al:Characteristic expression of sulfoglycosphingolipids in emdometrial adenocarcinoma cell lines derived from well differentiated endometrial adenocarcinoma. Manuscript in preparation.

• 14) Mikami M, Tsukazaki K, Nozawa S, et al:Menstrual cycle-associated expression of 2-hydroxy fatty acylphytosphingosine-containing Glccer, Laccer and Gb2Cer in human uterine endometrium. Biochim Biophys Acta 1125:104-109, 1992.

• 15) Mikami M, Kubushiro K, Tsukazaki K, et al:Neutral glycosphingolipids in human uterine endometrial cancer with alteration of ceramide molecular species in relation to differentiation. Submitted for publication.

• 16) Aruffo A, Kolanus W, Walz G, et al:CD62/P-selection recognition of myeloid and tumor cell sulfatides. Cell 67:35-44, 1991.

• 17) 野澤志朗ほか:子宮体癌. 医療 8:41, 1992,

• 18) 宇田川康博ほか:子宮癌細胞診における諸問題-子宮体癌を中心として-. Karkinos 6:429-434, 1993.

• 19) Tsukazaki K, et al:Abnormal expression of blood group-related antigens in uterine endometrial cancer. Jap J Cancer Res 82:934-941, 1991.

• 20) Nozawa S, et al:A monoclonal antibody (MSN-1) against a newly establishied uterine endonletrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry. Am J Obstet Gynecol 161:1079-1086, 1989.

• 21) 塚崎克己ほか:子宮体癌の発生に伴う複合糖質の発現異常とその臨床へのフィードバック. 取り扱い規約に沿った腫瘍鑑別診断アトラス-子宮体部-(森脇昭介, 杉森 甫編著), pp 123-143, 1993.

P.287 掲載の参考文献

• 1) 入村達郎ほか:がんの浸潤・転移研究マニュアル. がん転移研究会編, 金芳堂, 1994.

• 2) 済木育夫:細胞接着の制御と癌転移の阻止. 癌の悪性化と転移 (清水元治編), pp 157-163, 中外医学社, 東京, 1993.

• 3) Shiozaki H, Tahara H, Oka H:Expression of immunoreactive E-cadherin adhesion molecule in human cancer. Am J Pathol 139:17-23, 1991.
  pubmed

• 4) Sugimoto Y, Ohara T, Tsuruo T:Acquisition of metastatic ability and hybridomas between two low metastatic clones of murine colon adenocarcinoma 26 defective in either platelet-aggregating activity or in vitro growth potential. Cancer Res 47:4396-4401, 1987.
  pubmed

• 5) Takada A, Omori K, Kannagi R, et al:Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vas-cular emdothelium, Cancer Res 53:354-361, 1993,

• 6) Hoff SD, Matsushita Y, Ota DM, et al:Increased expression of sialyl-dimeric Lex antigen in liver metastasis of human colorectal carcinoma. Cancer Res 49:6883-6888, 1989.

• 7) 桐山幸三, 渡辺 正:癌の浸潤, 転移と糖鎖抗原. 複合糖質 (神奈木玲児編), pp 67-75, メジ カルビュー社, 東京, 1994.

• 8) Shimano R, Mori M, Sugimachi K, et al:Immunohistochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma. Am J Gastroenterol 89:101-105, 1994,

• 9) Hirohashi S, Shimosato Y. Ino Y, et al:Distribution of blood group antigen and CA 19-9 in gastric cancers and non-neoplastic gastric mucosa. Gann 75:540-547, 1984,
  pubmed

• 10) Hirohashi S, Ino Y, Kodama T, et al:Distribution of blood group antigens A, B, H and I (Ma) in mucus-producing adenocarcinoma of human lung. J Natl Cancer Inst 72:1299-1305, 1984.

• 11) Lee AK, Delellis RA, Rosan PP, et al:ABH blood group iso-antigen expression in breast carcinoma-An immunohistochemical evalution using monoclonal antibodies. Am J Clin Pathol 83:308-319, 1985.

• 12) Yuan M, Itzkowitz SH, Palekar A, et al:Distribution of blood group antigens A, B, H, Lewisa and Lewisb in human normal, fetal and malignant colonic tissue. Cancer Res 45:4499-4511, 1985.

• 13) Tsukazaki K, Sakayori M, Arai H, et al:Abnormal expression of blood group-related antigens in uterine endometrial cancers. Jpn J Cancer Res 82:934-941, 1991.
  pubmed

• 14) Nozawa S, Sakayori M, Ohta K, et al:A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry, Am J Obstet Gynecol 161:1079-1086, 1989.
  pubmed

• 15) Iwamori M, Sakayori M, Nozawa S, et al:Monoclonal antibody-defined antigen of human uterine endometrial carcinoma is Leb. J Biochem 105:718-722, 1989.

• 16) 塚崎克己:子宮体癌の発生に伴う複合糖質発現異常に関する基礎的研究とその臨床へのフィードバック. 日産婦誌 45:789-801, 1993.

• 17) Kubushiro K, Tsukazaki K, Sakuma Y, et al:Enzymatic basis for the accumulation of Lewis b antigen in uterine endometrial cancer. Jpn J Cancer Res 96:361-367, 1995.

• 18) Uemura M, Sakaguchi T, Uejima T, et al:Mouse monoclonal antibodies which recognize a human (β1-4) galactosyl-transferase associated with tumor in body fluids. Cancer Res 52:6153-6157, 1992,

• 19) 塚崎克己, 野澤志朗:子宮体癌の発生に伴う複合糖質の発現異常とその臨床へのフィードバック. 取扱い規約に沿った腫瘍鑑別診断アトラス「子宮体部」, pp 123-143, 森脇昭介, 杉森 甫 編著, 文光堂. 1993.

• 20) Kubushiro K, Tsukazaki K, Sakuma Y, et al:Expression mechanism of human uterine endometrial cancer-specific fucosylated carbohydrate chains; Aberrant 1-4fucosyltarnsferases in uterine endometrial cancer-derived cell lines with type I carbohydrate chains. Int J Oncol 6:93-97, 1995.
  pubmed

• 21) Negler A, Peacock M, Tantoco M, et al:Separation of hematopoietic progenitorcells from human umbilical cord blood. J Hematotherapy 2:243-245, 1993.

• 22) Netland PA, Zatter BR:Organ-specific adhesion of metastatic tumor cells in vitro. Science 224:1113-1114, 1984,

• 23) 久布白兼行, 塚崎克己, 佐久間雄一ほか:子宮体癌における糖鎖発現異常とその機序. 日本臨牀 53:197 (1753)-203 (1759), 1995.

• 24) 久布白兼行, 塚崎克己, 佐久間雄一ほか:子宮体癌における MSN-1認識抗原の組織接着および転移に与える影響. 日産婦誌 47:163-164, 1995.

• 25) Albini A, lwamoto Y, Kleinman HK, et al:A rapid in vitro assay for quqntitating the invasive potential of tumor cells. Cancer Res 47:3239-3245, 1987.

• 26) Masri K, Appert HE, Fukuda MN, et al:Identification of the full-length coding sequence for human galactosyltranferase (β-N-acetylglucosaminide; β1,4-gala-ctosyltransferase). Biochem Biophys Res Commun 157:657-663, 1988.

• 27) Ma J, Kubushiro K, Tashima Y, et al:Expression of β1,4-Galactosyltransferase in gynecological cancer cell lines. Int J Oncol 11:117-122, 1997,

• 28) Yoshiki J, Kubushiro K, Yoshida Y, et al:High expression of Uridine Diphosphate-galactose:LC3 Cerβ1-3 galactosyltransferase in human uterine endometrial cancer-derived cells as measured by enzyme linked immunosorbent assay and thin layer chromatography immunostaining. Jpn J Cancer Res 88(7):669-677, 1997,

• 29) Kubushiro K, Tsukazaki K, Nozawa S:Aberrant expression of glycoconjugates in endometrial cancer. Clinical significance and association with cell biology. Acta Histochem Cytochem 29:300-301, 1996.

P.298 掲載の参考文献

• 1) Blaese RM:Development of gene therapy for immunodeficiency; adenosine deaminase deficiency. Pediatr Res 33:S 49-S 55, 1993.

• 2) Miller AD:Human gene therapy comes of age. Nature 357:455-460, 1992.
  pubmed

• 3) 大橋十也:実験医学 12:333-339, 1994.

• 4) 島田 隆:実験医学 12:303-307, 1994.

• 5) Zabner J, et al:Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelial of patients with cystic fibrosis, cell 75:207-216, 1993.

• 6) 鐘ケ江裕美, 徳田千賀志, 斎藤 泉:アデノウイルスベクターと遺伝子治療.実験医学 12:316-322, 1994.

• 7) Fearon ER, Vogelstein BA:A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.

• 8) Imamura T, Arima T, Kato H, et al:Chromosomal deletions and K-ras gene mutations in human endometrial carcinoma. International Journal of Cancer 51:47-52, 1992.

• 9) Honda T, Kato K, Imamura T, et al:Involvement of p 53 gene mutations in human endometrial carcinomas. International Journal of Cancer 53:963-967, 1963,

• 10) Gima T, Kato H, Honda T, et al:DCC Gene Alteration in Human Endometrial Carcinomas. International Journal of Cancer 57:480-485, 1994,
  pubmed

• 11) Wake N, Gima T, Nishida J, et al:Accumulation of genetic events in endometrial carcinoma and its cell growth inhibition by antisense oligonucleotide complementary to the mutated K-ras gene. Cancer Molecular Biology 1:145-156, 1994.

• 12) 今村利朗, 和気徳夫:子宮体癌の遺伝子診断と遺伝子治療. 臨婦産 47:1404-1405, 1993.

• 13) Sirasawa S, Furuse M, Yokoyama N, et al:Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85-88, 1993.

• 14) 村上 章:遺伝子を制御する "アンチセンスDNA法". 化学 46(10):681-684, 1991.

• 15) Steven A Rosenberg:Gene therapy for cancer. JAMA 268:2416-2419, 1992,

• 16) A speeding ticker for NIH's contraversial cancer star. Science 259:1391-1392.1993.

• 17) Culver KW, et al:In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Sciehce 256:1550-1552, 1992.
  pubmed